scispace - formally typeset
F

Fatima Cardoso

Researcher at Champalimaud Foundation

Publications -  474
Citations -  36237

Fatima Cardoso is an academic researcher from Champalimaud Foundation. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 71, co-authored 411 publications receiving 28844 citations. Previous affiliations of Fatima Cardoso include The Breast Cancer Research Foundation & Groote Schuur Hospital.

Papers
More filters
Journal ArticleDOI

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A. Goldhirsch, +57 more
- 01 Sep 2013 - 
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
Journal ArticleDOI

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

TL;DR: Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.